Olverembatinib (HQP1351): a third-generation tyrosine kinase inhibitor in the treatment of hematologic and solid malignancies-a comprehensive review of clinical outcomes.

The increasing prevalence of cancers, their economic impact and the complications associated with existing treatments, have stimulated research to better understand the mechanisms involved in their aetiology and the development of more effective diagnostic and treatment methods. Olverembatinib (HQP1351 or GZD824) is a new third-generation tyrosine kinase inhibitor (TKI), that is being investigated for its potential application in the treatment of several cancers, with a focus on chronic myeloid leukemia (CML). This review attempts to summarise the pre-clinical and clinical studies in hematological and non-hematological malignancies of this agent.